# Assessment of AFP and PIVKA-II as Prognostic Indicators in Liver Transplantation for Hepatocellular Carcinoma

> **NCT06331260** · — · NOT_YET_RECRUITING · sponsor: **Zhejiang University** · enrollment: 600 (estimated)

## Conditions studied

- Liver Transplantation
- Hepatocellular Carcinoma
- Alpha-Fetoprotein
- Protein Induced by Vitamin K Absence or Antagonist-II

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06331260
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2028-04-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2024-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06331260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06331260, "Assessment of AFP and PIVKA-II as Prognostic Indicators in Liver Transplantation for Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06331260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*